Predictors of Hepatic Decompensation after Yttrium90 Transarterial Radioembolization—Optimizing Patient Selection

Predictors of Hepatic Decompensation after Yttrium90 Transarterial Radioembolization—Optimizing Patient Selection

Purpose Yttrium 90 (Y90) transarterial radioembolization (TARE) is effective for unresectable hepatocellular carcinoma (HCC) or to bridge/downstage before transplant; however, optimal patient selection is not well-described. This study aims to identify factors that increase risk of liver...

Full description

Saved in:
Bibliographic Details
Main Authors: Amelia Wong, Shirley Cheng, Anthony Herrera, Linda Wong
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2024-08-01
Series:Journal of Clinical Interventional Radiology ISVIR
Subjects:
hepatocellular carcinoma
yttrium 90
transarterial radioembolization
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1786711
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Yttrium 90 (Y90) transarterial radioembolization (TARE) is effective for unresectable hepatocellular carcinoma (HCC) or to bridge/downstage before transplant; however, optimal patient selection is not well-described. This study aims to identify factors that increase risk of liver decompensation resulting in hospital admissions after TARE.
ISSN:2456-4869

Similar Items